ロード中...
嵌合抗原受体-T细胞治疗儿童肿瘤的临床研究进展
Nowadays, the 5-year survival rate of childhood cancer patients can be more than 80%, but some patients with relapse and refractory cancers have shown no good response to traditional strategies. Chimeric antigen receptor engineered T (CAR-T) cell therapy is promising for these patients. CAR-T cells...
保存先:
| 出版年: | Zhongguo Dang Dai Er Ke Za Zhi |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
中国当代儿科杂志编辑部
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7389329/ https://ncbi.nlm.nih.gov/pubmed/29132473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7499/j.issn.1008-8830.2017.11.018 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|